The Evolving Role of α-Blockers in Benign Prostatic Hyperplasia and Beyond

[摘要] The paradigm for the medical management of benign prostatic hyperplasia (BPH) has undergone significant change over the past 15 years. Guided by new research, the approval of novel pharmaceutical and minimally invasive therapies, and the economics of health care financing, physicians have altered their approach to patient care in distinct ways. This evolution in thinking continues today. Indeed, as novel therapeutic modalities become available, as new connections between symptoms and sexual function become identified, and as we learn which baseline parameters best predict treatment response in particular patient populations, the therapeutic paradigm is likely to evolve and progress still further.

[学科分类] 基础医学